Serveur d'exploration sur l'automédication dans le monde francophone

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.

Identifieur interne : 000132 ( Main/Exploration ); précédent : 000131; suivant : 000133

Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.

Auteurs : S. Weibel [France] ; O. Menard [France] ; A. Ionita [France] ; M. Boumendjel [France] ; C. Cabelguen [France] ; C. Kraemer [France] ; J-A Micoulaud-Franchi [France] ; S. Bioulac [France] ; N. Perroud [Suisse] ; A. Sauvaget [France] ; L. Carton [France] ; M. Gachet [France] ; R. Lopez [France]

Source :

RBID : pubmed:31610922

Descripteurs français

English descriptors

Abstract

Attention deficit with or without hyperactivity disorder (ADHD) is one of the most frequent neuropsychiatric disorders, and affects 2-4% of adults. In contrast with many European countries, the identification and management of adult ADHD remains underdeveloped in France, and a subject of controversy. This review provides a practical update on current knowledge about ADHD in adults for French-speaking professionals who have to detect or manage adult patients with ADHD. ADHD is classified as a neurodevelopmental disorder in the recent update of the international diagnostic classification. While symptoms and impairment due to ADHD are frequently severe during childhood, they often evolve as children grow older, with frequent persistent disabilities in adulthood. In adulthood, the clinical presentation, as in childhood, involves the symptom triad of inattention, hyperactivity and impulsivity. However, differences are noted: hyperactivity is more often internalized, symptoms of inattention may be masked by anxiety symptoms or obsessive-like compensation strategies. ADHD is often diagnosed during childhood, but it is not rare for the diagnosis to be made later. Failure to recognise symptoms resulting in misdiagnosis, or alternatively well-developed compensation factors could be two underlying reasons for the long delay until diagnosis. Other symptoms, such as emotional deregulation or executive function-related symptoms are also usually observed in adults. In addition, in adults, ADHD is often associated with other psychiatric disorders (in 80% of cases); this makes the diagnosis even more difficult. These disorders encompass a broad spectrum, from mood disorders (unipolar or bipolar), to anxiety disorders, and other neurodevelopmental disorders and personality disorders, especially borderline and antisocial personality disorder. Substance-use disorders are very common, either as a consequence of impulsivity and emotional dysregulation or as an attempt at self-treatment. Sleep disorders, especially restless leg syndrome and hypersomnolence, could share common pathophysiological mechanisms with ADHD. ADHD and comorbidity-related symptoms are responsible for serious functional impairment, in various domains, leading to academic, social, vocational, and familial consequences. The impact on other psychiatric disorders as an aggravating factor should also be considered. The considerable disability and the poorer quality of life among adults with ADHD warrant optimal evaluation and management. The diagnostic procedure for ADHD among adults should be systematic. Once the positive diagnosis is made, the evaluation enables characterisation of the levels of severity and impairment at individual level. A full examination should also assess medical conditions associated with ADHD, to provide personalized care. In recent years, a growing number of assessment tools have been translated and validated in French providing a wide range of structured interviews and standardized self-report questionnaires for the evaluation of core and associated ADHD symptoms, comorbidities and functional impairment. The treatment of ADHD in adults is multimodal, and aims to relieve the symptoms, limit the burden of the disease, and manage comorbidities. The most relevant and validated psychological approaches are psycho-education, cognitive-behavioural therapy and "third wave therapies" with a specific focus on emotional regulation. Cognitive remediation and neurofeedback are promising strategies still under evaluation. Medications, especially psychostimulants, are effective for alleviating ADHD symptoms with a large effect size. Their safety and tolerance are satisfactory, although their long-term clinical benefit is still under discussion. In France, methylphenidate is the only stimulant available for the treatment of ADHD. Unfortunately, there is no authorization for its use among adults except in continuation after adolescence. Hence the prescription, which is subject to the regulations on narcotics, is off-label in France. This article aims to provide practical considerations for the management of ADHD and associated disorders in adults, in this particular French context.

DOI: 10.1016/j.encep.2019.06.005
PubMed: 31610922


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.</title>
<author>
<name sortKey="Weibel, S" sort="Weibel, S" uniqKey="Weibel S" first="S" last="Weibel">S. Weibel</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1114, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France. Electronic address: sebastien.weibel@chru-strasbourg.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1114, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Menard, O" sort="Menard, O" uniqKey="Menard O" first="O" last="Menard">O. Menard</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service d'addictologie, Hôpital Fontan 2, CHRU de Lille, 59000 Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'addictologie, Hôpital Fontan 2, CHRU de Lille, 59000 Lille</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ionita, A" sort="Ionita, A" uniqKey="Ionita A" first="A" last="Ionita">A. Ionita</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinique du château, Nightingale hospitals Paris, 92380 Garches, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinique du château, Nightingale hospitals Paris, 92380 Garches</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Garches</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Boumendjel, M" sort="Boumendjel, M" uniqKey="Boumendjel M" first="M" last="Boumendjel">M. Boumendjel</name>
<affiliation wicri:level="3">
<nlm:affiliation>Équipe de liaison et de soins en addictologie (ELSA), service de psychiatrie et d'addictologie, centre de soin de prévention et d'accompagnement en addictologie (CSAPA), Hôpital André Mignot, 78000 Versailles, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Équipe de liaison et de soins en addictologie (ELSA), service de psychiatrie et d'addictologie, centre de soin de prévention et d'accompagnement en addictologie (CSAPA), Hôpital André Mignot, 78000 Versailles</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Versailles</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Cabelguen, C" sort="Cabelguen, C" uniqKey="Cabelguen C" first="C" last="Cabelguen">C. Cabelguen</name>
<affiliation wicri:level="3">
<nlm:affiliation>Unité de neuromodulation et de psychiatrie de liaison, centre ambulatoire pluridisciplinaire de psychiatrie et d'addictologie, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de neuromodulation et de psychiatrie de liaison, centre ambulatoire pluridisciplinaire de psychiatrie et d'addictologie, Centre Hospitalier Universitaire de Nantes, 44000 Nantes</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kraemer, C" sort="Kraemer, C" uniqKey="Kraemer C" first="C" last="Kraemer">C. Kraemer</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Micoulaud Franchi, J A" sort="Micoulaud Franchi, J A" uniqKey="Micoulaud Franchi J" first="J-A" last="Micoulaud-Franchi">J-A Micoulaud-Franchi</name>
<affiliation wicri:level="4">
<nlm:affiliation>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author>
<name sortKey="Bioulac, S" sort="Bioulac, S" uniqKey="Bioulac S" first="S" last="Bioulac">S. Bioulac</name>
<affiliation wicri:level="4">
<nlm:affiliation>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author>
<name sortKey="Perroud, N" sort="Perroud, N" uniqKey="Perroud N" first="N" last="Perroud">N. Perroud</name>
<affiliation wicri:level="1">
<nlm:affiliation>Service des spécialités psychiatrique, département de santé mentale et de psychiatrie, Hôpitaux Universitaires de Genève, 1201 Genève, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Service des spécialités psychiatrique, département de santé mentale et de psychiatrie, Hôpitaux Universitaires de Genève, 1201 Genève</wicri:regionArea>
<wicri:noRegion>1201 Genève</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sauvaget, A" sort="Sauvaget, A" uniqKey="Sauvaget A" first="A" last="Sauvaget">A. Sauvaget</name>
<affiliation wicri:level="4">
<nlm:affiliation>Addictologie and psychiatrie de liaison, CHU de Nantes, 44000 Nantes, France; Laboratoire "mouvement, interactions, performance" (EA 4334), Faculté Sciences du sport, Université de Nantes, 44000 Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Addictologie and psychiatrie de liaison, CHU de Nantes, 44000 Nantes, France; Laboratoire "mouvement, interactions, performance" (EA 4334), Faculté Sciences du sport, Université de Nantes, 44000 Nantes</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
<orgName type="university">Université de Nantes</orgName>
</affiliation>
</author>
<author>
<name sortKey="Carton, L" sort="Carton, L" uniqKey="Carton L" first="L" last="Carton">L. Carton</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm U1171 "Troubles cognitifs dégénératifs et vasculaires", Université de Lille, 59000 Lille, France; Département de pharmacologie médicale, CHRU de Lille, 59000 Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U1171 "Troubles cognitifs dégénératifs et vasculaires", Université de Lille, 59000 Lille, France; Département de pharmacologie médicale, CHRU de Lille, 59000 Lille</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gachet, M" sort="Gachet, M" uniqKey="Gachet M" first="M" last="Gachet">M. Gachet</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service d'urgence et post-urgence psychiatrique, hôpital Lapeyronie, 34000 Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'urgence et post-urgence psychiatrique, hôpital Lapeyronie, 34000 Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lopez, R" sort="Lopez, R" uniqKey="Lopez R" first="R" last="Lopez">R. Lopez</name>
<affiliation wicri:level="3">
<nlm:affiliation>Consultation spécialisée TDAH adulte, centre national de référence narcolepsie hypersomnies rares, département de neurologie, Hôpital Gui-De-Chauliac, 34000 Montpellier, France; Inserm U1061, 34000 Montpellier, France. Electronic address: r-lopez@chu-montpellier.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Consultation spécialisée TDAH adulte, centre national de référence narcolepsie hypersomnies rares, département de neurologie, Hôpital Gui-De-Chauliac, 34000 Montpellier, France; Inserm U1061, 34000 Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31610922</idno>
<idno type="pmid">31610922</idno>
<idno type="doi">10.1016/j.encep.2019.06.005</idno>
<idno type="wicri:Area/Main/Corpus">000332</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000332</idno>
<idno type="wicri:Area/Main/Curation">000332</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000332</idno>
<idno type="wicri:Area/Main/Exploration">000332</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.</title>
<author>
<name sortKey="Weibel, S" sort="Weibel, S" uniqKey="Weibel S" first="S" last="Weibel">S. Weibel</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1114, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France. Electronic address: sebastien.weibel@chru-strasbourg.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1114, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Menard, O" sort="Menard, O" uniqKey="Menard O" first="O" last="Menard">O. Menard</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service d'addictologie, Hôpital Fontan 2, CHRU de Lille, 59000 Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'addictologie, Hôpital Fontan 2, CHRU de Lille, 59000 Lille</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ionita, A" sort="Ionita, A" uniqKey="Ionita A" first="A" last="Ionita">A. Ionita</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinique du château, Nightingale hospitals Paris, 92380 Garches, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinique du château, Nightingale hospitals Paris, 92380 Garches</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Garches</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Boumendjel, M" sort="Boumendjel, M" uniqKey="Boumendjel M" first="M" last="Boumendjel">M. Boumendjel</name>
<affiliation wicri:level="3">
<nlm:affiliation>Équipe de liaison et de soins en addictologie (ELSA), service de psychiatrie et d'addictologie, centre de soin de prévention et d'accompagnement en addictologie (CSAPA), Hôpital André Mignot, 78000 Versailles, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Équipe de liaison et de soins en addictologie (ELSA), service de psychiatrie et d'addictologie, centre de soin de prévention et d'accompagnement en addictologie (CSAPA), Hôpital André Mignot, 78000 Versailles</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Versailles</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Cabelguen, C" sort="Cabelguen, C" uniqKey="Cabelguen C" first="C" last="Cabelguen">C. Cabelguen</name>
<affiliation wicri:level="3">
<nlm:affiliation>Unité de neuromodulation et de psychiatrie de liaison, centre ambulatoire pluridisciplinaire de psychiatrie et d'addictologie, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de neuromodulation et de psychiatrie de liaison, centre ambulatoire pluridisciplinaire de psychiatrie et d'addictologie, Centre Hospitalier Universitaire de Nantes, 44000 Nantes</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kraemer, C" sort="Kraemer, C" uniqKey="Kraemer C" first="C" last="Kraemer">C. Kraemer</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Micoulaud Franchi, J A" sort="Micoulaud Franchi, J A" uniqKey="Micoulaud Franchi J" first="J-A" last="Micoulaud-Franchi">J-A Micoulaud-Franchi</name>
<affiliation wicri:level="4">
<nlm:affiliation>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author>
<name sortKey="Bioulac, S" sort="Bioulac, S" uniqKey="Bioulac S" first="S" last="Bioulac">S. Bioulac</name>
<affiliation wicri:level="4">
<nlm:affiliation>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author>
<name sortKey="Perroud, N" sort="Perroud, N" uniqKey="Perroud N" first="N" last="Perroud">N. Perroud</name>
<affiliation wicri:level="1">
<nlm:affiliation>Service des spécialités psychiatrique, département de santé mentale et de psychiatrie, Hôpitaux Universitaires de Genève, 1201 Genève, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Service des spécialités psychiatrique, département de santé mentale et de psychiatrie, Hôpitaux Universitaires de Genève, 1201 Genève</wicri:regionArea>
<wicri:noRegion>1201 Genève</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sauvaget, A" sort="Sauvaget, A" uniqKey="Sauvaget A" first="A" last="Sauvaget">A. Sauvaget</name>
<affiliation wicri:level="4">
<nlm:affiliation>Addictologie and psychiatrie de liaison, CHU de Nantes, 44000 Nantes, France; Laboratoire "mouvement, interactions, performance" (EA 4334), Faculté Sciences du sport, Université de Nantes, 44000 Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Addictologie and psychiatrie de liaison, CHU de Nantes, 44000 Nantes, France; Laboratoire "mouvement, interactions, performance" (EA 4334), Faculté Sciences du sport, Université de Nantes, 44000 Nantes</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
<orgName type="university">Université de Nantes</orgName>
</affiliation>
</author>
<author>
<name sortKey="Carton, L" sort="Carton, L" uniqKey="Carton L" first="L" last="Carton">L. Carton</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm U1171 "Troubles cognitifs dégénératifs et vasculaires", Université de Lille, 59000 Lille, France; Département de pharmacologie médicale, CHRU de Lille, 59000 Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U1171 "Troubles cognitifs dégénératifs et vasculaires", Université de Lille, 59000 Lille, France; Département de pharmacologie médicale, CHRU de Lille, 59000 Lille</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gachet, M" sort="Gachet, M" uniqKey="Gachet M" first="M" last="Gachet">M. Gachet</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service d'urgence et post-urgence psychiatrique, hôpital Lapeyronie, 34000 Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'urgence et post-urgence psychiatrique, hôpital Lapeyronie, 34000 Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lopez, R" sort="Lopez, R" uniqKey="Lopez R" first="R" last="Lopez">R. Lopez</name>
<affiliation wicri:level="3">
<nlm:affiliation>Consultation spécialisée TDAH adulte, centre national de référence narcolepsie hypersomnies rares, département de neurologie, Hôpital Gui-De-Chauliac, 34000 Montpellier, France; Inserm U1061, 34000 Montpellier, France. Electronic address: r-lopez@chu-montpellier.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Consultation spécialisée TDAH adulte, centre national de référence narcolepsie hypersomnies rares, département de neurologie, Hôpital Gui-De-Chauliac, 34000 Montpellier, France; Inserm U1061, 34000 Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">L'Encephale</title>
<idno type="ISSN">0013-7006</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult (MeSH)</term>
<term>Aging (psychology)</term>
<term>Attention Deficit Disorder with Hyperactivity (diagnosis)</term>
<term>Attention Deficit Disorder with Hyperactivity (drug therapy)</term>
<term>Attention Deficit Disorder with Hyperactivity (psychology)</term>
<term>Attention Deficit Disorder with Hyperactivity (therapy)</term>
<term>Central Nervous System Stimulants (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Methylphenidate (therapeutic use)</term>
<term>Psychotherapy (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Méthylphénidate (usage thérapeutique)</term>
<term>Psychothérapie (MeSH)</term>
<term>Stimulants du système nerveux central (MeSH)</term>
<term>Trouble déficitaire de l'attention avec hyperactivité (diagnostic)</term>
<term>Trouble déficitaire de l'attention avec hyperactivité (psychologie)</term>
<term>Trouble déficitaire de l'attention avec hyperactivité (thérapie)</term>
<term>Trouble déficitaire de l'attention avec hyperactivité (traitement médicamenteux)</term>
<term>Vieillissement (psychologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Methylphenidate</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Central Nervous System Stimulants</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Attention Deficit Disorder with Hyperactivity</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Trouble déficitaire de l'attention avec hyperactivité</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Attention Deficit Disorder with Hyperactivity</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr">
<term>Trouble déficitaire de l'attention avec hyperactivité</term>
<term>Vieillissement</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Aging</term>
<term>Attention Deficit Disorder with Hyperactivity</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Attention Deficit Disorder with Hyperactivity</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Trouble déficitaire de l'attention avec hyperactivité</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Trouble déficitaire de l'attention avec hyperactivité</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Méthylphénidate</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Humans</term>
<term>Psychotherapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Humains</term>
<term>Psychothérapie</term>
<term>Stimulants du système nerveux central</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Attention deficit with or without hyperactivity disorder (ADHD) is one of the most frequent neuropsychiatric disorders, and affects 2-4% of adults. In contrast with many European countries, the identification and management of adult ADHD remains underdeveloped in France, and a subject of controversy. This review provides a practical update on current knowledge about ADHD in adults for French-speaking professionals who have to detect or manage adult patients with ADHD. ADHD is classified as a neurodevelopmental disorder in the recent update of the international diagnostic classification. While symptoms and impairment due to ADHD are frequently severe during childhood, they often evolve as children grow older, with frequent persistent disabilities in adulthood. In adulthood, the clinical presentation, as in childhood, involves the symptom triad of inattention, hyperactivity and impulsivity. However, differences are noted: hyperactivity is more often internalized, symptoms of inattention may be masked by anxiety symptoms or obsessive-like compensation strategies. ADHD is often diagnosed during childhood, but it is not rare for the diagnosis to be made later. Failure to recognise symptoms resulting in misdiagnosis, or alternatively well-developed compensation factors could be two underlying reasons for the long delay until diagnosis. Other symptoms, such as emotional deregulation or executive function-related symptoms are also usually observed in adults. In addition, in adults, ADHD is often associated with other psychiatric disorders (in 80% of cases); this makes the diagnosis even more difficult. These disorders encompass a broad spectrum, from mood disorders (unipolar or bipolar), to anxiety disorders, and other neurodevelopmental disorders and personality disorders, especially borderline and antisocial personality disorder. Substance-use disorders are very common, either as a consequence of impulsivity and emotional dysregulation or as an attempt at self-treatment. Sleep disorders, especially restless leg syndrome and hypersomnolence, could share common pathophysiological mechanisms with ADHD. ADHD and comorbidity-related symptoms are responsible for serious functional impairment, in various domains, leading to academic, social, vocational, and familial consequences. The impact on other psychiatric disorders as an aggravating factor should also be considered. The considerable disability and the poorer quality of life among adults with ADHD warrant optimal evaluation and management. The diagnostic procedure for ADHD among adults should be systematic. Once the positive diagnosis is made, the evaluation enables characterisation of the levels of severity and impairment at individual level. A full examination should also assess medical conditions associated with ADHD, to provide personalized care. In recent years, a growing number of assessment tools have been translated and validated in French providing a wide range of structured interviews and standardized self-report questionnaires for the evaluation of core and associated ADHD symptoms, comorbidities and functional impairment. The treatment of ADHD in adults is multimodal, and aims to relieve the symptoms, limit the burden of the disease, and manage comorbidities. The most relevant and validated psychological approaches are psycho-education, cognitive-behavioural therapy and "third wave therapies" with a specific focus on emotional regulation. Cognitive remediation and neurofeedback are promising strategies still under evaluation. Medications, especially psychostimulants, are effective for alleviating ADHD symptoms with a large effect size. Their safety and tolerance are satisfactory, although their long-term clinical benefit is still under discussion. In France, methylphenidate is the only stimulant available for the treatment of ADHD. Unfortunately, there is no authorization for its use among adults except in continuation after adolescence. Hence the prescription, which is subject to the regulations on narcotics, is off-label in France. This article aims to provide practical considerations for the management of ADHD and associated disorders in adults, in this particular French context.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">31610922</PMID>
<DateCompleted>
<Year>2021</Year>
<Month>01</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2021</Year>
<Month>01</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0013-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>46</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2020</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>L'Encephale</Title>
<ISOAbbreviation>Encephale</ISOAbbreviation>
</Journal>
<ArticleTitle>Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.</ArticleTitle>
<Pagination>
<MedlinePgn>30-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0013-7006(19)30250-7</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2019.06.005</ELocationID>
<Abstract>
<AbstractText>Attention deficit with or without hyperactivity disorder (ADHD) is one of the most frequent neuropsychiatric disorders, and affects 2-4% of adults. In contrast with many European countries, the identification and management of adult ADHD remains underdeveloped in France, and a subject of controversy. This review provides a practical update on current knowledge about ADHD in adults for French-speaking professionals who have to detect or manage adult patients with ADHD. ADHD is classified as a neurodevelopmental disorder in the recent update of the international diagnostic classification. While symptoms and impairment due to ADHD are frequently severe during childhood, they often evolve as children grow older, with frequent persistent disabilities in adulthood. In adulthood, the clinical presentation, as in childhood, involves the symptom triad of inattention, hyperactivity and impulsivity. However, differences are noted: hyperactivity is more often internalized, symptoms of inattention may be masked by anxiety symptoms or obsessive-like compensation strategies. ADHD is often diagnosed during childhood, but it is not rare for the diagnosis to be made later. Failure to recognise symptoms resulting in misdiagnosis, or alternatively well-developed compensation factors could be two underlying reasons for the long delay until diagnosis. Other symptoms, such as emotional deregulation or executive function-related symptoms are also usually observed in adults. In addition, in adults, ADHD is often associated with other psychiatric disorders (in 80% of cases); this makes the diagnosis even more difficult. These disorders encompass a broad spectrum, from mood disorders (unipolar or bipolar), to anxiety disorders, and other neurodevelopmental disorders and personality disorders, especially borderline and antisocial personality disorder. Substance-use disorders are very common, either as a consequence of impulsivity and emotional dysregulation or as an attempt at self-treatment. Sleep disorders, especially restless leg syndrome and hypersomnolence, could share common pathophysiological mechanisms with ADHD. ADHD and comorbidity-related symptoms are responsible for serious functional impairment, in various domains, leading to academic, social, vocational, and familial consequences. The impact on other psychiatric disorders as an aggravating factor should also be considered. The considerable disability and the poorer quality of life among adults with ADHD warrant optimal evaluation and management. The diagnostic procedure for ADHD among adults should be systematic. Once the positive diagnosis is made, the evaluation enables characterisation of the levels of severity and impairment at individual level. A full examination should also assess medical conditions associated with ADHD, to provide personalized care. In recent years, a growing number of assessment tools have been translated and validated in French providing a wide range of structured interviews and standardized self-report questionnaires for the evaluation of core and associated ADHD symptoms, comorbidities and functional impairment. The treatment of ADHD in adults is multimodal, and aims to relieve the symptoms, limit the burden of the disease, and manage comorbidities. The most relevant and validated psychological approaches are psycho-education, cognitive-behavioural therapy and "third wave therapies" with a specific focus on emotional regulation. Cognitive remediation and neurofeedback are promising strategies still under evaluation. Medications, especially psychostimulants, are effective for alleviating ADHD symptoms with a large effect size. Their safety and tolerance are satisfactory, although their long-term clinical benefit is still under discussion. In France, methylphenidate is the only stimulant available for the treatment of ADHD. Unfortunately, there is no authorization for its use among adults except in continuation after adolescence. Hence the prescription, which is subject to the regulations on narcotics, is off-label in France. This article aims to provide practical considerations for the management of ADHD and associated disorders in adults, in this particular French context.</AbstractText>
<CopyrightInformation>Copyright © 2019 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Weibel</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1114, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France. Electronic address: sebastien.weibel@chru-strasbourg.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Menard</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Service d'addictologie, Hôpital Fontan 2, CHRU de Lille, 59000 Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ionita</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Clinique du château, Nightingale hospitals Paris, 92380 Garches, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boumendjel</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Équipe de liaison et de soins en addictologie (ELSA), service de psychiatrie et d'addictologie, centre de soin de prévention et d'accompagnement en addictologie (CSAPA), Hôpital André Mignot, 78000 Versailles, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cabelguen</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Unité de neuromodulation et de psychiatrie de liaison, centre ambulatoire pluridisciplinaire de psychiatrie et d'addictologie, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kraemer</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Service de psychiatrie 2, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Micoulaud-Franchi</LastName>
<ForeName>J-A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bioulac</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Service d'explorations fonctionnelles du système nerveux, clinique du sommeil, CHU de Bordeaux, 33000 Bordeaux, France; CNRS, SANPSY, USR 3413, SANPSY, Université de Bordeaux, 33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perroud</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Service des spécialités psychiatrique, département de santé mentale et de psychiatrie, Hôpitaux Universitaires de Genève, 1201 Genève, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sauvaget</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Addictologie and psychiatrie de liaison, CHU de Nantes, 44000 Nantes, France; Laboratoire "mouvement, interactions, performance" (EA 4334), Faculté Sciences du sport, Université de Nantes, 44000 Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carton</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Inserm U1171 "Troubles cognitifs dégénératifs et vasculaires", Université de Lille, 59000 Lille, France; Département de pharmacologie médicale, CHRU de Lille, 59000 Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gachet</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Service d'urgence et post-urgence psychiatrique, hôpital Lapeyronie, 34000 Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lopez</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Consultation spécialisée TDAH adulte, centre national de référence narcolepsie hypersomnies rares, département de neurologie, Hôpital Gui-De-Chauliac, 34000 Montpellier, France; Inserm U1061, 34000 Montpellier, France. Electronic address: r-lopez@chu-montpellier.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2019</Year>
<Month>10</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Encephale</MedlineTA>
<NlmUniqueID>7505643</NlmUniqueID>
<ISSNLinking>0013-7006</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>207ZZ9QZ49</RegistryNumber>
<NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008774" MajorTopicYN="N">Methylphenidate</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adult ADHD</Keyword>
<Keyword MajorTopicYN="N">Comorbidity</Keyword>
<Keyword MajorTopicYN="N">Comorbidité</Keyword>
<Keyword MajorTopicYN="N">Diagnosis</Keyword>
<Keyword MajorTopicYN="N">Diagnostic</Keyword>
<Keyword MajorTopicYN="N">Methylphenidate</Keyword>
<Keyword MajorTopicYN="N">Méthylphénidate</Keyword>
<Keyword MajorTopicYN="N">Psychotherapy</Keyword>
<Keyword MajorTopicYN="N">Psychothérapie</Keyword>
<Keyword MajorTopicYN="N">TDAH de l’adulte</Keyword>
<Keyword MajorTopicYN="N">Traitement</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2019</Year>
<Month>01</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2019</Year>
<Month>05</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2019</Year>
<Month>06</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2019</Year>
<Month>10</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2021</Year>
<Month>1</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2019</Year>
<Month>10</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">31610922</ArticleId>
<ArticleId IdType="pii">S0013-7006(19)30250-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.encep.2019.06.005</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
<li>Suisse</li>
</country>
<region>
<li>Alsace (région administrative)</li>
<li>Aquitaine</li>
<li>Grand Est</li>
<li>Hauts-de-France</li>
<li>Languedoc-Roussillon</li>
<li>Nord-Pas-de-Calais</li>
<li>Nouvelle-Aquitaine</li>
<li>Occitanie (région administrative)</li>
<li>Pays de la Loire</li>
<li>Île-de-France</li>
</region>
<settlement>
<li>Bordeaux</li>
<li>Garches</li>
<li>Lille</li>
<li>Montpellier</li>
<li>Nantes</li>
<li>Strasbourg</li>
<li>Versailles</li>
</settlement>
<orgName>
<li>Université de Bordeaux</li>
<li>Université de Nantes</li>
</orgName>
</list>
<tree>
<country name="France">
<region name="Grand Est">
<name sortKey="Weibel, S" sort="Weibel, S" uniqKey="Weibel S" first="S" last="Weibel">S. Weibel</name>
</region>
<name sortKey="Bioulac, S" sort="Bioulac, S" uniqKey="Bioulac S" first="S" last="Bioulac">S. Bioulac</name>
<name sortKey="Boumendjel, M" sort="Boumendjel, M" uniqKey="Boumendjel M" first="M" last="Boumendjel">M. Boumendjel</name>
<name sortKey="Cabelguen, C" sort="Cabelguen, C" uniqKey="Cabelguen C" first="C" last="Cabelguen">C. Cabelguen</name>
<name sortKey="Carton, L" sort="Carton, L" uniqKey="Carton L" first="L" last="Carton">L. Carton</name>
<name sortKey="Gachet, M" sort="Gachet, M" uniqKey="Gachet M" first="M" last="Gachet">M. Gachet</name>
<name sortKey="Ionita, A" sort="Ionita, A" uniqKey="Ionita A" first="A" last="Ionita">A. Ionita</name>
<name sortKey="Kraemer, C" sort="Kraemer, C" uniqKey="Kraemer C" first="C" last="Kraemer">C. Kraemer</name>
<name sortKey="Lopez, R" sort="Lopez, R" uniqKey="Lopez R" first="R" last="Lopez">R. Lopez</name>
<name sortKey="Menard, O" sort="Menard, O" uniqKey="Menard O" first="O" last="Menard">O. Menard</name>
<name sortKey="Micoulaud Franchi, J A" sort="Micoulaud Franchi, J A" uniqKey="Micoulaud Franchi J" first="J-A" last="Micoulaud-Franchi">J-A Micoulaud-Franchi</name>
<name sortKey="Sauvaget, A" sort="Sauvaget, A" uniqKey="Sauvaget A" first="A" last="Sauvaget">A. Sauvaget</name>
</country>
<country name="Suisse">
<noRegion>
<name sortKey="Perroud, N" sort="Perroud, N" uniqKey="Perroud N" first="N" last="Perroud">N. Perroud</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000132 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000132 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31610922
   |texte=   Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31610922" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021